Core Insights - Approximately 30-40% of erectile dysfunction (ED) patients do not respond to phosphodiesterase-5 inhibitors (PDE5i) monotherapy, which includes drugs like Viagra, Cialis, and Levitra, indicating a significant unmet medical need for more effective treatments [2][4] - Palatin Technologies is developing a new co-formulation of bremelanotide (BMT) and a PDE5i, which is expected to be more effective for ED patients who do not respond to existing PDE5i therapies [3][8] - A Phase 2 clinical study of this co-formulation is currently underway, with topline data expected by the end of 2024, and a Phase 3 study anticipated to start in the first half of 2025 [1][9] Company Overview - Palatin Technologies is a biopharmaceutical company focused on developing first-in-class medicines that modulate the melanocortin receptor systems, targeting diseases with significant unmet medical needs [5] - The company aims to maximize the commercial potential of its products through marketing collaborations with industry leaders [5] Clinical Study Details - The Phase 2 clinical trial is designed to enroll approximately 50 patients who are non-responders to PDE5i monotherapy, assessing the safety and efficacy of BMT co-administered with a PDE5i [9] - Previous studies have shown that bremelanotide has statistically significant and clinically meaningful effects on improving erectile function [10]

Core Insights - The article discusses the initiation of a Phase 2 clinical study by Palatin Technologies to evaluate the co-administration of bremelanotide, an MC4R agonist, with tirzepatide (GLP-1/GIP) for obesity treatment, with topline data expected by the end of 2024 [1][8] Company Overview - Palatin Technologies is a biopharmaceutical company focused on developing first-in-class medicines that modulate melanocortin receptor systems, targeting diseases with significant unmet medical needs and commercial potential [5][8] Clinical Study Details - The Phase II study, titled "BMT-801," has FDA clearance and aims to enroll up to 60 patients currently on tirzepatide across five trial sites in the U.S. The study will assess the safety and efficacy of bremelanotide as a standalone treatment or in conjunction with GLP-1/GIP therapy [2][8] Obesity Context - Obesity, defined as a BMI ≥30 kg/m², is a growing public health concern linked to increased mortality and serious health conditions, with approximately 42% of U.S. adults and one in five teens affected [4][8] Mechanism of Action - Genetic analysis highlights the melanocortin 4 receptor (MC4R) as crucial in appetite regulation, with mutations leading to obesity. MC4R agonists are seen as promising targets for obesity treatments due to their role in promoting satiety [3][9]

Investors might want to bet on Palatin Technologies, Inc. (PTN) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the ...

Palatin Technologies, Inc. (NYSE:PTN) Q3 2024 Earnings Conference Call May 15, 2024 11:00 AM ET Company Participants Carl Spana - President, CEO & Director Stephen Wills - CFO, COO, EVP, Treasurer & Secretary Conference Call Participants Joe Pantginis - H.C. Wainwright & Co. Operator Greetings. Welcome to Palatin's Third Quarter Fiscal Year 2024 Operating Results Conference Call. [Operator Instructions]. As a reminder, this conference call is being recorded. Before we begin our remarks, I would like to remi ...

Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update EX-99.1 2 ptn_ex991.htm PRESS RELEASE EXHIBIT 99.1 CRANBURY, NJ – May 15, 2024 /PRNewswire/ – Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced financial results for its fiscal third quarter ended March 31, 2024. "Study results of our successful Phase 3 M ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to __________ Commission file number: 001-15543 PALATIN TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 95-4078884 (State ...

Fiscal Third Quarter Ended March 31, 2024 Business Highlights and Recent Updates Anti-Inflammatory / Autoimmune Programs (melanocortin receptor agonists) Positive Phase 3 PL9643 MELODY-1 Pivotal Study Results Co-Primary Symptom Endpoint of Pain Met Statistical Significance (P<0.025) and 7 of 11 Secondary Symptom Endpoints Met Statistical Significance (P<0.05), at the12-Week Treatment Period Rapid Onset of Efficacy and Multiple Symptom Endpoints, Including the Co-Primary Pain Endpoint, Met Statistical Signif ...

CORPORATE PRESENTATION February 2024 Stephen T. Wills, CPA/MST CFO / COO 2 3 Vyleesi®(bremelanotide) Hypoactive Sexual Desire Disorder * These programs are planned but dependent on funding. Ophthalmology MCr Programs Conjunctiva/Cornea/Ocular surface • Glaucoma | --- | --- | --- | --- | --- | --- | --- | |---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|------- ...

Palatin Technologies, Inc. (NYSE:PTN) Q2 2024 Earnings Conference Call February 15, 2024 11:00 AM ET Company Participants Carl Spana - President and Chief Executive Officer Steve Wills - Executive Vice President, Chief Financial Officer and Chief Operating Officer Conference Call Participants Joe Pantginis - H.C. Wainwright Michael Higgins - Ladenburg Thalmann John Newman - Canaccord Operator Greetings. Welcome to Palatin’s Second Quarter Fiscal Year 2024 Operating Results Conference Call. At this time, all ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to __________ Commission file number: 001-15543 PALATIN TECHNOLOGIES, INC. | Title of Each Class | Trading Symbol | Name of Each Exchange on Which Registe ...